Cara Therapeutics, Inc. (0HTC.L)
USD 4.52
(-9.57%)
USD 4.52
(-9.57%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 37.07 Million USD | 1833.21% |
| 2022 | 1.91 Million USD | 0.0% |
| 2021 | 1.91 Million USD | -47.78% |
| 2020 | 3.67 Million USD | 9.58% |
| 2019 | 3.35 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 38.37 Million USD | 3.5% |
| 2024 Q2 | 39.67 Million USD | -100.0% |
| 2023 FY | 37.07 Million USD | 1833.21% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | 6.81 Million USD | 0.0% |
| 2023 Q4 | 37.07 Million USD | 444.08% |
| 2022 Q1 | 1.45 Million USD | -24.14% |
| 2022 FY | 1.91 Million USD | 0.0% |
| 2022 Q4 | 1.91 Million USD | 285.92% |
| 2022 Q3 | 497 Thousand USD | -49.44% |
| 2022 Q2 | 983 Thousand USD | -32.44% |
| 2021 Q1 | 3.25 Million USD | -11.52% |
| 2021 Q3 | 2.37 Million USD | -15.79% |
| 2021 Q4 | 1.91 Million USD | -19.17% |
| 2021 FY | 1.91 Million USD | -47.78% |
| 2021 Q2 | 2.81 Million USD | -13.29% |
| 2020 Q1 | 3.09 Million USD | -7.64% |
| 2020 FY | 3.67 Million USD | 9.58% |
| 2020 Q3 | 2.69 Million USD | -9.06% |
| 2020 Q4 | 3.67 Million USD | 36.49% |
| 2020 Q2 | 2.95 Million USD | -4.43% |
| 2019 Q4 | 3.35 Million USD | -6.94% |
| 2019 FY | 3.35 Million USD | 0.0% |
| 2019 Q1 | 4.08 Million USD | 0.0% |
| 2019 Q2 | 3.84 Million USD | -5.82% |
| 2019 Q3 | 3.6 Million USD | -6.42% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 71.492% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 34.935% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 90.44% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 18.852% |
| bluebird bio, Inc. | 224.41 Million USD | 83.478% |
| Imunon, Inc. | 1.13 Million USD | -3154.562% |
| Editas Medicine, Inc. | 24.37 Million USD | -52.138% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.714% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 98.123% |
| Myriad Genetics, Inc. | 130.9 Million USD | 71.674% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 85.645% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -11.697% |
| Verastem, Inc. | 40.08 Million USD | 7.501% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.539% |
| Waters Corporation | 2.3 Billion USD | 98.392% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.882% |
| Biogen Inc. | 7.18 Billion USD | 99.484% |
| Nektar Therapeutics | 112.62 Million USD | 67.077% |
| Perrigo Company plc | 3.63 Billion USD | 98.979% |
| Dynavax Technologies Corporation | 252.41 Million USD | 85.31% |
| Illumina, Inc. | 1.48 Billion USD | 97.51% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -1044.897% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3607.9% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 78.66% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -57.522% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 93.748% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -10.634% |
| Evolus, Inc. | 120.35 Million USD | 69.193% |
| Adicet Bio, Inc. | 17.7 Million USD | -109.45% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1106.213% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.628% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 92.607% |
| FibroGen, Inc. | 89.69 Million USD | 58.662% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.644% |
| OPKO Health, Inc. | 222.03 Million USD | 83.3% |
| Homology Medicines, Inc. | 43.17 Million USD | 14.121% |
| Geron Corporation | 35.05 Million USD | -5.786% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.417% |
| Exelixis, Inc. | 189.94 Million USD | 80.479% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -3861.432% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 61.674% |
| Zoetis Inc. | 6.56 Billion USD | 99.435% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 79.177% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -742.322% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 94.884% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -8.45% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 97.352% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 96.726% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.527% |
| Blueprint Medicines Corporation | 610.96 Million USD | 93.931% |
| Insmed Incorporated | 1.19 Billion USD | 96.893% |
| TG Therapeutics, Inc. | 100.11 Million USD | 62.965% |
| Incyte Corporation | 29.16 Million USD | -27.148% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 91.696% |